Literature DB >> 11442217

Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence.

E A Lee1, K L Flanagan, K Odhiambo, W H Reece, C Potter, R Bailey, K Marsh, M Pinder, A V Hill, M Plebanski.   

Abstract

The merozoite surface protein-1 (MSP1) is the most studied malaria blood-stage vaccine candidate. Lymphokines such as interferon gamma (IFN-gamma) and interleukin 4 (IL-4) may mediate blood-stage specific protection. Here we identify Plasmodiumfalciparum MSP1 T-cell epitopes capable of rapid induction of IFN-gamma and/or IL-4 from peripheral blood mononuclear cells of East and West African donors. Both allelic forms of these novel MSP1 T-cell epitopes were stimulatory. An unusually high numbers of Gambian responders (> 80%) to these epitopes were observed, suggesting that MSPI reactivity may have been underestimated previously in this population. Surprisingly, IFN-gamma responses to allelic T-cell epitopes failed to correlate with differential antigenic exposure in The Gambia compared to Kenya. These results suggest an unexpected level of immunoregulation of IFN-gamma response with variable allelic T-cell reactivity independent of the level of antigenic exposure. Further analysis of the mechanisms determining this response pattern may be required if vaccines are to overcome this allelic reactivity bias in malaria-exposed populations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442217     DOI: 10.4269/ajtmh.2001.64.194

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  15 in total

Review 1.  Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.

Authors:  Magdalena Plebanski; Owen Proudfoot; Dodie Pouniotis; Ross L Coppel; Vasso Apostolopoulos; Graham Flannery
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes.

Authors:  Arlene E Dent; Christopher T Yohn; Peter A Zimmerman; John Vulule; James W Kazura; Ann M Moormann
Journal:  Am J Trop Med Hyg       Date:  2007-08       Impact factor: 2.345

3.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

4.  Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.

Authors:  Edwin A M Lee; Dupeh R Palmer; Katie L Flanagan; William H H Reece; Kennedy Odhiambo; Kevin Marsh; Margaret Pinder; Michael B Gravenor; Wendy A Keitel; Kent E Kester; Carter Diggs; David Kaslow; V Apostolopoulos; W Ripley Ballou; Adrian V S Hill; Urszula Krzych; Magdalena Plebanski
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.

Authors:  Anna L Goodman; C Epp; D Moss; A A Holder; J M Wilson; G P Gao; C A Long; E J Remarque; A W Thomas; V Ammendola; S Colloca; M D J Dicks; S Biswas; D Seibel; L M van Duivenvoorde; S C Gilbert; A V S Hill; S J Draper
Journal:  Infect Immun       Date:  2010-08-16       Impact factor: 3.441

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

7.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

8.  Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

Authors:  Susanne H Sheehy; Christopher J A Duncan; Sean C Elias; Katharine A Collins; Katie J Ewer; Alexandra J Spencer; Andrew R Williams; Fenella D Halstead; Samuel E Moretz; Kazutoyo Miura; Christian Epp; Matthew D J Dicks; Ian D Poulton; Alison M Lawrie; Eleanor Berrie; Sarah Moyle; Carole A Long; Stefano Colloca; Riccardo Cortese; Sarah C Gilbert; Alfredo Nicosia; Adrian V S Hill; Simon J Draper
Journal:  Mol Ther       Date:  2011-08-23       Impact factor: 11.454

9.  Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Authors:  Sean C Elias; Katharine A Collins; Fenella D Halstead; Prateek Choudhary; Carly M Bliss; Katie J Ewer; Susanne H Sheehy; Christopher J A Duncan; Sumi Biswas; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

10.  Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection.

Authors:  Arlene E Dent; Ann M Moormann; Christopher T Yohn; Rhonda J Kimmel; Peter O Sumba; John Vulule; Carole A Long; David L Narum; Brendan S Crabb; James W Kazura; Daniel J Tisch
Journal:  Malar J       Date:  2012-08-21       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.